Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed non-Hodgkin's lymphoma
• CD20+ disease
• Failed at least 1 prior standard systemic therapy
• Persistent lymphoma by physical examination, radiographic studies, bone marrow evaluations, flow cytometry, or polymerase chain reaction
• Tumor burden less than 500 cc by computed tomography or MRI
• * No splenomegaly
• Autologous hematopoietic stem cells or bone marrow harvested and cryopreserved
• * No circulating lymphoma cells by morphology or flow cytometry at or near the time of peripheral blood stem cell (PBSC) collection if unpurged PBSCs are to be used
• * 10% or less marrow involvement by flow cytometry or morphology if purged bone marrow is to be used
• No CNS lymphoma
• No chronic lymphocytic leukemia or small lymphocytic lymphoma/well-differentiated lymphocytic lymphoma
• PATIENT CHARACTERISTICS:
• Age
• 60 to 80
• Performance status
• SWOG 0-1
• Life expectancy
• More than 60 days
• Hematopoietic
• See Disease Characteristics
• Hepatic
• Bilirubin less than 1.5 mg/dL
• Renal
• Creatinine less than 2.0 mg/dL
• Cardiovascular
• No active coronary artery disease
• Pulmonary
• FEV\_1 at least 70% of expected
• Vital capacity at least 70% of expected
• Other
• Not pregnant
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• Able to perform self-care during radiation isolation
• No major organ dysfunction
• No major infection
• No circulating anti-mouse antibody
• No other serious medical condition considered to represent contraindications to bone marrow transplantation
• No competing causes of death that would predict life span to be less than 10 additional years
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No prior bone marrow or stem cell transplantation
• Chemotherapy
• Not specified
• Endocrine therapy
• Not specified
• Radiotherapy
• No prior radiotherapy greater than 20 Gy to any critical normal organ (e.g., lung, liver, spinal cord, or more than 25% of red marrow)
• Surgery
• Not specified
• Other
• More than 30 days since prior systemic antilymphoma therapy